Back to top

Cantor Fitzgerald Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)

Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Rocket Pharmaceuticals yesterday and set a price target of $15.00. The company...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Rocket Pharmaceuticals, Inc. (RCKT)